Be the first to review this item
Etaperazin (Perphenazinum, Perphenazine) - antipsychotic (neuroleptic) piperazine derivative of phenothiazine. It is believed that the antipsychotic effects of phenothiazines due to blockade of the postsynaptic dopamine receptors in mesolimbic brain structures. Perphenazine has a strong antiemetic effect, the central mechanism of which is associated with inhibition or blockade of dopamine D2-receptors in the chemoreceptor trigger zone of the cerebellum and peripheral - to the blockade of the vagus nerve in the digestive tract. It has adrenoblokiruyuschey alpha activity. Anticholinergic activity and sedation may occur from mild to moderate intensity, the hypotensive effect is weak. It has expressed extrapyramidal effects. Antiemetic effect may intensify anticholinergic and sedative properties. It has a muscle-relaxing effect.
Treatment of psychotic disorders, especially for excitation and hyperactivity, schizophrenia; neuroses, accompanied by fear, stress. Treatment of nausea and vomiting of various aetiologies. Itching.
Cirrhosis, hepatitis, hemolytic jaundice, nephritis, disorders of hematopoiesis, myxedema, progressive system of the brain and spinal cord disease, decompensated heart disease, thromboembolic disease, later stage bronchiectasis, pregnancy, lactation, hypersensitivity to perphenazine.
With careful use perphenazine if you are hypersensitive to other drugs in the phenothiazine series.
With caution used phenothiazines in patients with pathological changes in the blood picture, the human liver, alcohol intoxication, Reye's syndrome, as well as in breast cancer, cardiovascular disease, predisposition to the development of glaucoma, Parkinson's disease, gastric ulcer and duodenal ulcer , urinary retention, chronic respiratory diseases (especially in children), seizures, vomiting; in elderly patients (increased risk of excessive sedation and hypotensive effect), in emaciated and debilitated patients.
The development of tardive dyskinesia during treatment with perphenazine more likely in the elderly, women, and brain damage. Parkinsonian extrapyramidal reactions are more common in elderly patients, dystonic extrapyramidal reactions - in younger people. Symptoms of these disorders may occur in the first few days of treatment or after prolonged therapy and may be renewed even after a single dose.
In the event of hyperthermia, which is one of the elements of the CSN, perphenazine should be lifted immediately.
Avoid the simultaneous application of phenothiazines with absorbent antidiarrheals.
During treatment, avoid alcohol.
Recommendations for the use of perphenazine in children have not been established up to 12 years. In children, especially with acute diseases, when used phenothiazines more likely to develop extrapyramidal symptoms.
Effects on ability to drive vehicles and management mechanisms
It should be used with caution in patients involved in potentially hazardous activities that require high speed of psychomotor reactions.
For adults and children while taking over 12 years into the daily dose is 4-80 mg. In chronic course of the disease and in resistant cases, the daily dose may be increased up to 150-400 mg. The frequency of administration and duration of treatment set individually.
Important notice- the outer box design may vary before prior notice!